Streetbeat News

Regulatory

BLUE

Bluebird Bio is set to present new and updated data from its gene therapy programs in sickle cell disease and beta-thalassemia at the 65th ASH Annual Meeting and Exposition. The presentation will detail efficacy, safety, and health-related quality of life data in adult and pediatric patients treated with lovo-cel and beti-cel.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:38 pm

UBER

Uber has reached an agreement with New York Attorney General Letitia James, providing drivers with benefits and protections such as a minimum earnings standard and paid sick leave. The agreement also resolves the classification issue in New York. As part of the agreement, Uber will provide drivers with a minimum earnings floor, paid sick leave, in-app support in multiple languages, appeal options, and paid training. This follows a recent agreement with the New York State Department of Labor, where Uber will pay into the state's unemployment insurance fund.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:30 pm

MBIO

Mustang Bio has announced that data related to its MB-106 CD20-Targeted CAR-T therapy has been selected for presentation at the 65th ASH Annual Meeting. This suggests that the company's research is being recognized by the scientific community.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:29 pm

AFMD

Affimed N.V. (NASDAQ:AFMD) announced the presentation of Phase 1/2 data from AFM13 in combination with allogeneic NK cells at the 2023 ASH Annual Meeting. The treatment showed a 94.4% objective response rate and a 72.2% complete response rate in 36 patients with CD30-positive lymphoma. The company also announced two upcoming presentations on its lead innate cell engager (ICE®) AFM13 at the ASH 2023 Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:24 pm

PTGX

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has announced that five abstracts related to its rusfertide program have been accepted for presentation at the 65th American Society of Hematology Annual Meeting and Exposition. The presentations will cover new data on rusfertide's potential therapeutic value in the treatment of Polycythemia Vera and other diseases, as well as epidemiological aspects of PV and preclinical data on a hepcidin mimetic treatment in a mouse model for sickle cell disease.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:23 pm

GMAB

Genmab A/S (NASDAQ:GMAB) announced that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody, have been accepted for presentation and publication at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH). The presentations will include data from several trials evaluating the safety and efficacy of epcoritamab as a monotherapy or in combination for the treatment of patients with various lymphoma subtypes. Results from a phase 1/2 trial evaluating GEN3014, an investigational novel human CD38 monoclonal antibody, in patients with relapsed/refractory multiple myeloma will also be presented.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:23 pm

ELDN

Eledon Pharmaceuticals (NASDAQ:ELDN) has reported positive results from its ongoing Phase 1b trial evaluating tegoprubart for the prevention of kidney transplant rejection. The data from 11 participants showed that tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated. The company will continue the study in parallel with its Phase 2 BESTOW study.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:22 pm

AGIO

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that it will present a broad set of clinical and translational data from its programs at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. The presentations will focus on rare blood disorders, including PK deficiency, thalassemia, sickle cell disease and anemia associated with lower-risk myelodysplastic syndromes (LR-MDS). The company's drug Mitapivat showed statistically significant hemoglobin response in Phase 2 of the RISE UP study in Sickle Cell Disease, supporting its advancement to Phase 3. Agios will also host a live and webcast investor event on Dec. 11, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:22 pm

VRTX

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that seven abstracts have been accepted for presentation at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition. This includes two presentations of updated clinical data from pivotal Phase 3 trials investigating exagamglogene autotemcel's potential as a one-time functional cure for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Five additional abstracts, including two on the improvements in patients' quality of life following treatment with exa-cel, have also been accepted.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:21 pm

INBX

Inhibrx, Inc. (NASDAQ:INBX) has announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan and Temozolomide for the treatment of advanced or metastatic, unresectable Ewing sarcoma. The disease control rate was 76.9% among the 13 patients evaluated. The treatment was well tolerated with the most common adverse events being diarrhea, nausea, and fatigue.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:20 pm